Today it was announced that pharmaceuticals are not exempt from Trump’s tariffs. How does this apply to medical devices? Are most devices manufactured offshore? Mr. Wittes: It’s company by company, ...

Please tell us about Puma Biotechnology. Mr. Auerbach: I’d be more than happy to. Puma is a biotech company that is dedicated to the development and commercialization of drugs for the treatment of ...

How is your coverage weathering the tariff storm? Dr. Brozak: Our life sciences dedicated franchise, WBB Securities, is the busiest we’ve ever been in the history of the firm, and the life sciences ...

Let’s start with an overview of the company and some notable milestones. Mr. Levy: Sure. You know, a major challenge for cancer patients and their caregivers today is that while we’ve seen incredible ...

Let’s start with a look at your coverage, and how it might have changed since we spoke in 2023. Mr. Lichtman: Sure. I cover a large group of medical device companies from micro cap to mega cap. I ...

Please update us on what you’re doing now. It looks like you founded a new firm. Mr. Singh: I left Oppenheimer last year, after an 18-year career; 10 years on the sell side, and 15 total between buy- ...

Bear market investing protection from Jeremy A. Ellis of Campbell Newman Asset Management and Jeffrey Lent, Torray Investment ...

We’ve spoken before, but just for readers who may not be familiar, let’s start with a refresher on the company, its mission, and some milestones. Mr. Do: BioVie has two assets that we are currently ...

Please give us a brief overview of NeurAxis and its services. Mr. Carrico: Sure. NeurAxis is an early growth stage med-tech company, focused on treating disorders of the gut-brain interaction in the ...

The Wall Street Transcript is a completely unique resource for investors and business researchers.

TWST: For the benefit of our readers, let’s start with an introduction to Hodges Capital Management. Tell us a bit about the firm’s history and your business ...